ArticleFrontiers in oncology2022

Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma.

Karolina Piechna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.